| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2019-05-21 | Santhera Pharmaceuticals (Switzerland) Biozentrum, University of Basel (Switzerland) | LAMA2-deficient congenital muscular dystrophy | research - development - collaboration | Rare diseases - Genetic diseases - Neuromuscular diseases | Collaboration agreement | |
| 2019-05-21 | Jacobs (USA - TX) WuXi Biologics (China) | biologics drug substance manufacturing facility in Dundalk (Ireland) | services contract | Technology - Services | Construction of new premises | |
| 2019-05-21 | Wuxi Biologics (China) Wuxi Vaccines (China) undisclosed global vaccine leader | construction of new premises - services contract | Technology - Services - Infectious diseases | Services contract | ||
| 2019-05-16 | Wuxi Biologics (China) | integrated manufacturing center for innovative biologics | construction of new premises | Technology - Services | Construction of new premises | |
| 2019-05-13 | Oxford Genetics (UK) Cell and Gene Therapy Catapult (UK) | scalable Lentiviral manufacturing processes based | collaboration | Technology - Services | Collaboration agreement | |
| 2019-04-25 | Precigen (USA-MD) | opening of new premises | Rare diseases - Genetic diseases - Technology - Services | Opening of new premises | ||
| 2019-04-24 | Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA) | ARO-HBV and up to three additional RNA interference (RNAi) therapeutics | hepatitis B | licensing - research | Infectious diseases | Milestone |
| 2019-04-23 | Audentes Therapeutics (USA - CA) | opening of new premises | Rare diseases - Genetic diseases | Opening of new premises | ||
| 2019-04-22 | Eli Lilly (USA - IN) Avidity Biosciences (USA - CA) | new medicines in immunology and other selected indications. | research - licensing | Immunological diseases | Licensing agreement | |
| 2019-04-16 | Novasep (France) Theravectys (France) | DNA Flap Technology for GMP Manufacturing of lentiviral vectors | licensing | Technology - Services | Licensing agreement | |
| 2019-04-16 | Wuxi Biologics (China) I-Mab Biopharma (China) | manufacturing - production | Technology - Services | Production agreement | ||
| 2019-04-09 | Wuxi Biologics (China) NBE-Therapeutics (Switzerland) | NBE-002 (anti-ROR1) | development - production - manufacturing | Technology - Services - Cancer - Oncology | Production agreement | |
| 2019-04-09 | Wuxi Biologics (China) NBE-Therapeutics (Switzerland) | NBE-002 (anti-ROR1) | development - production - manufacturing | Technology - Services - Cancer - Oncology | Production agreement | |
| 2019-04-08 | Genzyme (USA - MA), a Sanofi company (France) - Alnylam Pharmaceuticals (USA - MA) | RNAi therapeutics including ALN-AT3, fitusiran, patisiran and ALN-TTRsc02 | rare genetic diseases including hemophilia A, hemophilia B | development - commercialisation | Rare diseases - Genetic diseases | Termination of an agreement |
| 2019-04-08 | Alnylam Pharmaceuticals (USA - MA) Regeneron Pharmaceuticals (USA - NY) | RNAi compounds | development - commercialisation | CNS diseases - Ophtalmological diseases - Liver diseases - Hepatic diseases | Development agreement | |
| 2019-04-01 | Avexis, a Novartis company (Switzerland) AstraZeneca (UK) | biologics therapy manufacturing campus in Longmont | plant acquisition | Technology - Services | Plant acquisition | |
| 2019-03-26 | Eli Lilly (USA - IN) ImmuNext (USA - NH) | preclinical novel target that could lead to potential new medicines for autoimmune diseases by regulating immune cell metabolism | research - licensing | Autoimmune diseases | Research agreement | |
| 2019-03-25 | MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY) | production site designed to manufacture late-stage and commercially-approved cell and gene therapy products | construction of new premises | Technology - Services | Construction of new premises | |
| 2019-03-22 | Bluebird bio (USA - MA) | manufacturing facility in Durham | opening of new premises | Rare diseases - Genetic diseases - Technology - Services | Opening of new premises | |
| 2019-03-19 | Merck KGaA (Germany) GenScript (USA-NJ/China) | plasmid and viral vector manufacturing | collaboration | Technology - Services | Collaboration agreement |
